يعرض 1 - 10 نتائج من 6,250 نتيجة بحث عن '"Vascular Disease"', وقت الاستعلام: 1.43s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
  3. 3
  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية
  6. 6
  7. 7
    دورية أكاديمية

    المؤلفون: Berg, Katherine M, Bray, Janet E, Ng, Kee-Chong, Liley, Helen G, Greif, Robert, Carlson, Jestin N, Morley, Peter T, Drennan, Ian R, Smyth, Michael, Scholefield, Barnaby R, Weiner, Gary M, Cheng, Adam, Djärv, Therese, Abelairas-Gómez, Cristian, Acworth, Jason, Andersen, Lars W, Atkins, Dianne L, Berry, David C, Bhanji, Farhan, Bierens, Joost, Bittencourt Couto, Thomaz, Borra, Vere, Böttiger, Bernd W, Bradley, Richard N, Breckwoldt, Jan, Cassan, Pascal, Chang, Wei-Tien, Charlton, Nathan P, Chung, Sung Phil, Considine, Julie, Costa-Nobre, Daniela T, Couper, Keith, Dainty, Katie N, Dassanayake, Vihara, Davis, Peter G, Dawson, Jennifer A, de Almeida, Maria Fernanda, De Caen, Allan R, Deakin, Charles D, Dicker, Bridget, Douma, Matthew J, Eastwood, Kathryn, El-Naggar, Walid, Fabres, Jorge G, Fawke, Joe, Fijacko, Nino, Finn, Judith C, Flores, Gustavo E, Foglia, Elizabeth E, Folke, Fredrik, Gilfoyle, Elaine, Goolsby, Craig A, Granfeldt, Asger, Guerguerian, Anne-Marie, Guinsburg, Ruth, Hatanaka, Tetsuo, Hirsch, Karen G, Holmberg, Mathias J, Hosono, Shigeharu, Hsieh, Ming-Ju, Hsu, Cindy H, Ikeyama, Takanari, Isayama, Tetsuya, Johnson, Nicholas J, Kapadia, Vishal S, Kawakami, Mandira Daripa, Kim, Han-Suk, Kleinman, Monica E, Kloeck, David A, Kudenchuk, Peter, Kule, Amy, Kurosawa, Hiroshi, Lagina, Anthony T, Lauridsen, Kasper G, Lavonas, Eric J, Lee, Henry C, Lin, Yiqun, Lockey, Andrew S, Macneil, Finlay, Maconochie, Ian K, Madar, R John, Malta Hansen, Carolina, Masterson, Siobhan, Matsuyama, Tasuku, McKinlay, Christopher JD, Meyran, Daniel, Monnelly, Vix, Nadkarni, Vinay, Nakwa, Firdose L, Nation, Kevin J, Nehme, Ziad, Nemeth, Michael, Neumar, Robert W, Nicholson, Tonia, Nikolaou, Nikolaos, Nishiyama, Chika, Norii, Tatsuya, Nuthall, Gabrielle A, Ohshimo, Shinchiro, Olasveengen, Theresa M, Ong, Yong-Kwang Gene, Orkin, Aaron M, Parr, Michael J, Patocka, Catherine, Perkins, Gavin D, Perlman, Jeffrey M, Rabi, Yacov, Raitt, James, Ramachandran, Shalini, Ramaswamy, Viraraghavan V, Raymond, Tia T, Reis, Amelia G, Reynolds, Joshua C, Ristagno, Giuseppe, Rodriguez-Nunez, Antonio, Roehr, Charles C, Rüdiger, Mario, Sakamoto, Tetsuya, Sandroni, Claudio, Sawyer, Taylor L, Schexnayder, Steve M, Schmölzer, Georg M, Schnaubelt, Sebastian, Semeraro, Federico, Singletary, Eunice M, Skrifvars, Markus B, Smith, Christopher M, Soar, Jasmeet, Stassen, Willem, Sugiura, Takahiro, Tijssen, Janice A, Topjian, Alexis A, Trevisanuto, Daniele, Vaillancourt, Christian, Wyckoff, Myra H, Wyllie, Jonathan P, Yang, Chih-Wei, Yeung, Joyce, Zelop, Carolyn M, Zideman, David A, Nolan, Jerry P, Collaborators

    جغرافية الموضوع: United States

    وصف الملف: Print-Electronic; application/pdf

    العلاقة: Circulation; (2023). Circulation, 148(24), e187-e280.; https://hdl.handle.net/2292/68768Test; 37942682 (pubmed)

  8. 8
    دورية أكاديمية

    المساهمون: Настоящее исследование выполнено в рамках фундаментальной темы № 1021051402790-6 «Изучение иммунопатологии, диагностики и терапии на ранних стадиях системных ревматических заболеваний».

    المصدر: Rheumatology Science and Practice; Vol 62, No 1 (2024); 81-89 ; Научно-практическая ревматология; Vol 62, No 1 (2024); 81-89 ; 1995-4492 ; 1995-4484

    وصف الملف: application/pdf

    العلاقة: https://rsp.mediar-press.net/rsp/article/view/3516/2351Test; England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: Mechanisms and implications. BMJ. 2018;23(361):1036. doi:10.1136/bmj.k1036; Balsa A, Lojo-Oliveira L, Alperi-López M, García-Manrique M, Ordóñez-Cañizares C, Pérez L, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: The Spanish cohort of the COMORA study. Reumatol Clin (Engl Ed). 2019;15(2):102-108. doi:10.1016/j.reuma.2017.06.002; Насонов ЕЛ (ред.). Российские клинические рекомендации. Ревматология. М.:ГЭОТАР-Медиа;2020.; Baghdadi LR, Woodman RJ, Shanahan EM, Mangoni AA. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: A systematic review and meta-analysis. PLoS One. 2015;10(2):0117952. doi:10.1371/journal.pone.0117952; Удачкина ЕВ, Новикова ДС, Попкова ТВ, Насонов ЕЛ. Роль интерлейкина 6 в развитии атеросклероза при ревматоидном артрите. Современная ревматология. 2013;7(3):25-32. doi:10.14412/1996-7012-2013-7; Eltoft A, Arntzen KA, Wilsgaard T, Mathiesen EB, Johnsen SH. Interleukin-6 is an independent predictor of progressive atherosclerosis in the carotid artery: The Tromsø Study. Atherosclerosis. 2018;271:1-8.; Lubrano V, Gabriele M, Puntoni MR, Longo V, Pucci L. Relationship among IL-6, LDL cholesterol and lipid peroxidation. Cell Mol Biol Lett. 2015;20(2):310-322. doi:10.1515/cmble-2015-0020; Barra LJ, Pope JE, Hitchon C, Boire G, Schieir O, Lin D, et al.; CATCH group. The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis. Rheumatology (Oxford). 2017;56(5):768-776. doi:10.1093/rheumatology/kew474; Насонов ЕЛ, Попкова ТВ. Атеросклероз: перспективы противовоспалительной терапии. Терапевтический архив. 2018;90(5):4-12. doi:10.26442/terarkh20189054-12; McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74(4):694-702. doi:10.1136/annrheumdis-2013-204345; Castagné B, Viprey M, Martin K, Schott A-M, Cucherat M, Soubrier M. Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis. PLoS One. 2019;14(8):0220178. doi:10.1371/journal.pone.0220178; Jones G, Wallace T, McIntosh MJ, Brockwell L, Gómez-Reino JJ, Sebba A. Five-year efficacy and safety of tocilizumab monotherapy in patients with rheumatoid arthritis who were methotrexateand biologic-naive or free of methotrexate for 6 months: The AMBITION study. J Rheumatol. 2017;44(2):142-146. doi:10.3899/jrheum.160287; Насонов ЕЛ, Лила АМ. Ингибиция интерлейкина 6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017;55(6):590-599. doi:10.14412/1995-4484-2017-590-599; Комитет экспертов РКО. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика. 2011;10(6 Прил. 2.):46.; Герасимова ЕВ, Попкова ТВ, Мартынова АВ, Кириллова ИГ, Маркелова ЕИ, Семашко АС, и др. Динамика традиционных модифицируемых факторов риска, суммарного сердечно-сосудистого риска и структурных изменений сонных артерий у больных ревматоидным артритом на фоне длительной терапии ингибитором рецепторов интерлейкина-6. Научно-практическая ревматология. 2021;59(1):84-92. doi:10.47360/1995-4484-2021-84-92; Попкова ТВ, Новикова ДС, Панасюк ЕЮ, Авдеева АС, Удачкина ЕВ, Александрова ЕН, и др. Влияние тоцилизумаба на систему транспорта холестерина крови и ранние проявления атеросклероза у больных ревматоидным артритом. Терапевтический архив. 2012;84(5):9-18.; Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, Pulley J, et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1806-1812. doi:10.1136/annrheumdis-2015-207872; Toussirot E. The Interrelations between biological and targeted synthetic agents used in inflammatory joint diseases, and obesity or body composition. Metabolites. 2020;10(3):107. doi:10.3390/metabo10030107; Choi I, Sagawa A, Lee E, Lee EB, Song YW. Tocilizumab increases body weight and serum adipokine levels in patients with rheumatoid arthritis independently of their treatment response: A retrospective cohort study. J Korean Med Sci. 2020;35(22):e55. doi:10.3346/jkms.2020.35.e155; Tournadre A, Pereira B, Dutheil F, Giraud C, Courteix D, Sapin V, et al. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle. 2017;8(4):639-646. doi:10.1002/jcsm.12189; Wada E, Tanihata J, Iwamura A, Takeda S, Hayashi YK, Matsuda R. Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice. Skelet Muscle. 2017;7(1):23. doi:10.1186/s13395-017-0140-z; Ando K, Takahashi F, Kato M, Kaneko N, Doi T, Ohe Y, et al. Tocilizumab, a proposed therapy for the cachexia of interleukin 6-expressing lung cancer. PLoS One. 2014;9(7):e102436. doi:10.1371/journal.pone.0102436; Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968-2980. doi:10.1002/art.23940; Soubrier M, Pei J, Durand F, Gullestad L, John A. Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis: A post hoc analysis. Rheumatol Ther. 2017;4(1):133-149. doi:10.1007/s40744-016-0049-8; Hoffman E, Rahat MA, Feld J, Elias M, Rosner I, Kaly L, et al. Effects of tocilizumab, an anti-interleukin-6 receptor antibody, on serum lipid and adipokine levels in patients with rheumatoid arthritis. Int J Mol Sci. 2019;20(18):4633. doi:10.3390/ijms20184633; Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13:141. doi:10.1186/ar3455; IL6R Genetics Consortium Emerging Risk Factors Collaboration; Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012; 379(9822):1205-1213. doi:10.1016/S0140-6736(11)61931-4; Navarro G, Taroumian S, Barroso N, Duan L, Furs D. Tocilizumab in rheumatoid arthritis: A meta-analysis of efficacy and selected clinical conundrums. Semin Arthritis Rheum. 2014;43(4):458-469. doi:10.1016/j.semarthrit.2013.08.001; Kitas GD, Nightingale P, Armitage J, Sattar N, Belch JJF, Symmons DP. A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71(9):1437-1449. doi:10.1002/art.40892; Abeles AM, Pillinge MH. Statins as antiinflammatory and immunomodulatory agents: A future in rheumatologic therapy? Arthritis Rheumatol. 2006;54(2):393-407. doi:10.1002/art.21521; Halacoglu J, Shea LA. Cardiovascular risk assessment and therapeutic implications in rheumatoid arthritis. J Cardiovasc Transl Res. 2020;13:878-90. doi:10.1007/s12265-020-09964-9; Tanaka T, Narazaki M, Ogata A, Kishimoto T. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin Immunol. 2014;26(1):88-96. doi:10.1016/j.smim.2014.01.009; Cacciapaglia F, Anelli MG, Rinaldi A, Fornaro M, Lopalco G, Scioscia C, et al. Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment. Mediators Inflamm. 2018;2018:2453265. doi:10.1155/2018/2453265; Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, et al. Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: A multi-database cohort study. Arthritis Rheumatol. 2017;69(6):1154-1164. doi:10.1002/art.40084; Ferraz-Amaro I, Hernández-Hernández MV, Tejera-Segura B, Delgado-Frías E, Macía-Díaz M, Machado JD, et al. Effect of IL-6 receptor blockade on proprotein convertase subtilisin/kexin type9 and cholesterol efflux capacity in rheumatoid arthritis patients. Horm Metab Res. 2019;51(3):200-209. doi:10.1055/a-0833-4627; Strang AC, Bisoendial RJ, Kootte RS, Schulte DM, DallingaThie GM, Levels JH, et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis. 2013;229(1):174-181. doi:10.1016/j.atherosclerosis.2013.04.031; Ruiz-Limón P, Ortega R, Arias de la Rosa I, Abalos-Aguilera MDC, Perez-Sanchez C, Jimenez-Gomez Y, et al. Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. Transl Res. 2017;183:87-103. doi:10.1016/j.trsl.2016.12.003; Bacchiega BC, Bacchiega AB, Usnayo MJG, Bedirian R, Singh G, Pinheiro G. Interleukin 6 inhibition and coronary artery disease in a high-risk population: A prospective community-based clinical study. J Am Heart Assoc. 2017;6(3):e005038. doi:10.1161/JAHA.116.005038; Ikonomidis I, Pavlidis G, Katsimbri P, Andreadou I, Triantafyllidi H, Tsoumani M, et al. Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function. Clin Res Cardiol. 2019;108(10):1093-1101. doi:10.1007/s00392-019-01443-9; Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N. Tocilizumab monotherapy reduces arterial stiffness as effectively as An open-label randomized controlled trial. J Rheumatol. 2011;38(10):2169-2171. doi:10.3899/jrheum.110340; Chen DY, Chen YM, Hsieh TY, Hsieh CW, Lin CC, Lan JL. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17(1):52. doi:10.1186/s13075-015-0559-8; Rao VU, Pavlov A, Klearman M, Musselman D, Giles JT, Bathon JM, et al. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheumatol. 2015;67(2):372-380. doi:10.1002/art.38920; Okazaki S, Sakaguchi M, Miwa K, Furukado S, Yamagami H, Yagita Y, et al. Association of interleukin-6 with the progression of carotid atherosclerosis: A 9-year follow-up study. Stroke. 2014;45(10):2924-2929. doi:10.1161/STROKEAHA.114.005991; Puz P, Lasek-Bal A. Repeated measurements of serum concentrations of TNF-alpha, interleukin-6 and interleukin-10 in the evaluation of internal carotid artery stenosis progression. Atherosclerosis. 2017;263:97-103. doi:10.1016/j.atherosclerosis.2017.06.008; Pauli N, Puchałowicz K, Kuligowska A, Krzystolik A, Dziedziejko V, Safranow K, et al. Associations between IL-6 and echoparameters in patients with early onset coronary artery disease. Diagnostics (Basel). 2019;9(4):189. doi:10.3390/diagnostics9040189; Zhang J, Xie F, Yun H, Chen L, Muntner P, Levitan EB, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1813-1818. doi:10.1136/annrheumdis-2015-207870; Grange S, Schmitt C, Ganeshalingam K, Choy EH. Tocilizumab did not significantly increase serum cholesterol levels in healthy subjects. Rheumatology (Oxford). 2014;53:95-96. doi:10.1093/rheumatology/keu101.023; Specker C, Aringer M, Burmester GR, Killy B, Hofmann MW, Kellner H, et al. The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age. Clin Exp Rheumatol. 2022;40(9):1657-1665. doi:10.55563/clinexprheumatol/f7ff6q; Specker C, Alberding A, Aringer M, Burmester GR, Flacke JP, Hofmann MW, et al. ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis. Clin Exp Rheumatol. 2021;39(2):319-328. doi:10.55563/clinexprheumatol/3qdgi1; Jones G, Panova E. New insights and long-term safety of tocilizumab in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10(10):195-199. doi:10.1177/1759720X18798462; Gale S, Trinh H, Tuckwell K, Collinson N, Stone JH, Sarsour K, et al. Adverse events in giant cell arteritis and rheumatoid arthritis patient populations: Analyses of tocilizumab clinical trials and claims data. Rheumatol Ther. 2019;6(1):77-88. doi:10.1007/s40744-019-0139-5; https://rsp.mediar-press.net/rsp/article/view/3516Test

  9. 9
    دورية أكاديمية
  10. 10
    دورية أكاديمية